What was announced

On 16 September 2026, Anderon, an IBM company, finalised an agreement with the US Department of Commerce for a $1 billion award under the CHIPS and Science Act. IBM disclosed a further $1 billion of its own investment behind the business, taking the committed total to $2 billion. Anderon operates a 300-millimetre pure-play quantum wafer foundry at the Albany NanoTech Complex in New York, and its first quantum wafers are already running. The award was proposed on 21 May; September’s release is the definitive agreement.

The initial focus is superconducting quantum processors, and the foundry sells capacity to competing quantum hardware vendors rather than serving IBM alone. IBM published no revenue figure, no capacity figure and no milestone schedule alongside it.

What it is worth

Nothing in any guided period, which is a description rather than a complaint. IBM’s 2026 outlook calls for 4% to 5% constant-currency revenue growth and carries no quantum revenue. Management has not guided to any. The updated research report assumes Anderon contributes zero to the base case through 2027, exactly as its predecessor did.

The capital commitment is small enough to set aside. The dividend costs roughly $6.37 billion a year, $6.76 a share across 942.13 million shares, against $13.79 billion of trailing free cash flow: cover of 2.17 times. Charging the whole $1 billion to one year would take cover to 2.01 times, on the report’s own calculations. The dividend, the buyback and the balance sheet are untroubled either way.

What has changed is competitive position. This is the first pure-play quantum wafer foundry in the United States, half of it is paid for by the federal government, and it converts a research programme into an industrial asset. The report lifts its Competitive Advantage score from 7 to 8 and the bull-case fair value from $285 to $290. That is the full extent of the effect, and the market agreed: IBM led the Dow lower on the day of the announcement.

Why the rating holds

IBM stays at Watchlist. At $231.38 the shares sit 0.1% below where they were three weeks ago, on 18.1 times forward earnings, against a weighted fair value of $245.60. A newly funded quantum option and a 15 basis point rise in the ten-year Treasury very nearly cancelled each other out.

The question that decides this rating has nothing to do with quantum: whether the two-thirds of deferred deals management said would close actually closed. Third-quarter results on 21 October carry the answer. The price at which the shares become interesting is still $210 to $220.

Full workings are in the complete International Business Machines (IBM) report on our Reports page.

For more, browse our full equity research reports, check the earnings calendar for what's coming up, or head back to the blog for the latest updates.